22301479

PMC3356483

1K23AI079401/AI/NIAID NIH HHS/United States
1K23HD064814-01/HD/NICHD NIH HHS/United States
1K24HD058735-01/HD/NICHD NIH HHS/United States
1R01AI089489-01/AI/NIAID NIH HHS/United States
1R01FD003519-01/FD/FDA HHS/United States
1R01HD057956-02/HD/NICHD NIH HHS/United States
1U01AI082184-01/AI/NIAID NIH HHS/United States
1U10-HD45962-06/HD/NICHD NIH HHS/United States
1U181P000303/PHS HHS/United States
1U18IP000303-01/IP/NCIRD CDC HHS/United States
1UL 1RR024128-01/RR/NCRR NIH HHS/United States
3UL1RR025764-02S3/RR/NCRR NIH HHS/United States
HD060559-01/HD/NICHD NIH HHS/United States
HHSN267200700051C/HD/NICHD NIH HHS/United States
K23 AI079401/AI/NIAID NIH HHS/United States
K23 AI079401-01A1/AI/NIAID NIH HHS/United States
K23 HD064814/HD/NICHD NIH HHS/United States
K23 HD064814-01/HD/NICHD NIH HHS/United States
K24 HD058735/HD/NICHD NIH HHS/United States
K24 HD058735-01A1/HD/NICHD NIH HHS/United States
R01 AI089489-01/AI/NIAID NIH HHS/United States
R01 HD057956/HD/NICHD NIH HHS/United States
R01 HD057956-02/HD/NICHD NIH HHS/United States
R01 HD060559/HD/NICHD NIH HHS/United States
R01 HD060559-01A1/HD/NICHD NIH HHS/United States
R01 HD060559-02/HD/NICHD NIH HHS/United States
U01 AI082184-01/AI/NIAID NIH HHS/United States
U01-AI74419/AI/NIAID NIH HHS/United States
UL1 RR024128/RR/NCRR NIH HHS/United States
UL1 RR024128-01/RR/NCRR NIH HHS/United States
UL1 RR025764/RR/NCRR NIH HHS/United States
UL1 RR025764-02S3/RR/NCRR NIH HHS/United States

CDC Public Access

Voriconazole is the treatment of choice for invasive aspergillosis and its use is increasing in pediatrics. Minimal pharmacokinetic data exist in young children. We report voriconazole concentrations for 10 children <3 years of age and pharmacokinetic parameters for 1 infant who had therapeutic drug monitoring performed. Trough concentrations were unpredictable based on dose, highlighting the need to follow values during therapy.